Last Updated: May 2026
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator family, researched for vascular-endothelial-targeted bioregulation and blood vessel function. It is sequence-identical to Testagen — both are Lys-Glu-Asp tripeptides, with the Khavinson framework attributing their different proposed tissue targets to context-dependent effects. Vesugen is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.
Vesugen is a synthetic Lys-Glu-Asp tripeptide proposed to enter vascular endothelial cell nuclei and modulate gene expression in pathways related to endothelial function, vascular tone, and blood vessel maintenance. Within the Khavinson framework, Vesugen is the vascular-targeted complement to organ-specific bioregulators like Cardiogen (cardiac muscle) and Pinealon (pineal/brain). The Lys-Glu-Asp sequence is shared with Testagen. Evidence level: Preclinical; Khavinson-group research; independent replication limited.
Preclinical studies from the Khavinson group have reported effects on vascular endothelial function markers, blood vessel structure parameters in aging models, and gene expression markers in endothelial cell culture. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted. Russian clinical use has been reported in vascular aging and cardiovascular adjunctive contexts. Evidence level: Preclinical; Khavinson-group research; FDA-grade Phase 2/3 not conducted.
Vesugen is sequence-identical to Testagen at the tripeptide level (Lys-Glu-Asp), with the Khavinson framework attributing the different proposed tissue targets to context-dependent effects. This is the most notable Khavinson-cluster duplication.
| Bioregulator | Structure | Target tissue | Notable feature |
|---|---|---|---|
| Vesugen | Tripeptide (Lys-Glu-Asp) | Vascular endothelium | Same sequence as Testagen |
| Testagen | Tripeptide (Lys-Glu-Asp) | Testis | Same sequence as Vesugen |
| Cardiogen | Tetrapeptide (Ala-Glu-Asp-Arg) | Cardiac | Distinct sequence |
| Vilon | Dipeptide (Lys-Glu) | Immune | Lys-Glu (subset of Vesugen) |
Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards. Evidence level: Preclinical safety; human long-term unestablished.
Vesugen is not approved by the FDA, EMA, or any major Western regulator as of May 2026. Regulatory context in FDA peptide regulation 2025–2026 timeline.
Because Vesugen and Testagen share the identical Lys-Glu-Asp tripeptide sequence, mass spectrometry alone cannot distinguish them — they are the same molecule sold under different names with different proposed targets. Buyers should be aware that purchasing both as if they were distinct compounds is paying twice for one peptide. Independent HPLC purity testing remains the standard quality signal. Guidance in how-to-test-peptides hub.
Peptigrity purchases Vesugen vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The Testagen sequence-identity is flagged in our verification framework. Methodology in how we calculate trust scores.
Vesugen is proposed to act on vascular endothelial tissue through epigenetic gene-expression modulation, with preclinical research focused on endothelial function and vascular aging markers. Human Phase 2/3 efficacy is not established at Western clinical standards.
At the peptide-sequence level, yes — both are Lys-Glu-Asp tripeptides. The Khavinson framework attributes their different proposed tissue targets (vascular for Vesugen, testicular for Testagen) to context-dependent effects rather than sequence differences. Buyers paying for both as if they were different compounds are paying twice for the same molecule.
Vesugen is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.
No active FDA approval pathway exists for Vesugen as of May 2026.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Note that mass spec cannot distinguish Vesugen from Testagen at the peptide level. COA interpretation in red flags in peptide certificates of analysis.
No. Vesugen is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Vesugen is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.